Merck Animal Health, a division of Merck & Co., Inc., increased investment and expansion opportunities in its U.S. manufacturing and warehousing in Millsboro, Delaware.

The company expanded its manufacturing capacity and capabilities in Millsboro, which produces a range of animal health vaccines and pharmaceuticals for animal health diseases, last year, with additional expansion activities planned over the next few years.

“We are excited about the opportunity to bring capital improvements, expansion in our manufacturing capacity and capabilities, and advanced technology to our Millsboro facility, thereby, strengthening our footprint in the state and increasing our ability to fulfill customer demand for our portfolio of products,” said Bruce Lynch, Site Director, Merck Animal Health, Millsboro, Delaware.

“Our Merck Animal Health business is making great strides in building our business for the future. That means we need to ensure our place as a leader in animal health with a substantial and sustainable U.S. facility footprint, which includes investment and expansion in our key facilities. As a leader in delivering innovative pharmaceuticals and vaccines to advance animal health and meet customer needs, this investment reflects our commitment in producing a range of animal health vaccines and pharmaceuticals for animal health diseases,” he added.

“We are working diligently to create new ways and processes to better serve our customers and strengthen our investment in expanding our manufacturing and warehousing capacity and capabilities so that we remain a valued partner to our customers through our reliability, flexibility and responsiveness,” said Scott Bormann, Vice President, North America Commercial Operations, Merck Animal Health. “Our investment in Millsboro positions our company for strong long-term growth and emphasizes our dedication to the Science of Healthier Animals.”